SCHEMBL26807482

SCHEMBL26807482

Cn1cc(S(=O)(=O)Nc2nc(Oc3ccccc3)cc(C3CCC(C(=O)O)CC3)n2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 4/20 0.40
▸ HTR7 P34969 4/20 0.40
▸ JAK1 P23458 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ VCP P55072 4/20 0.37
▸ EGFR P00533 2/20 0.36
▸ FGFR1 P11362 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ OGG1 O15527 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ SLC8A1 P32418 1/20 0.36
▸ PDE4A P27815 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4C Q08493 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ TNK2 Q07912 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26807484 0.90 HTR1A (0.43) HTR1AHTR7JAK1SMN1; SMN2ALDH1A1
SCHEMBL29566649 0.89 HTR1A (0.42) HTR1AHTR7JAK1SMN1; SMN2ALDH1A1
SCHEMBL26807354 0.89 HTR1A (0.42) HTR1AHTR7JAK1SMN1; SMN2ALDH1A1
SCHEMBL26807485 0.87 HTR1A (0.40) HTR1AHTR7JAK1SMN1; SMN2EGFR
SCHEMBL24309397 0.86 HTR1A (0.40) HTR1AHTR7JAK1SMN1; SMN2ALDH1A1
SCHEMBL29566328 0.86 HTR1A (0.40) HTR1AHTR7JAK1SMN1; SMN2ALDH1A1
SCHEMBL26807486 0.82 HTR1A (0.41) HTR1AHTR7SMN1; SMN2LMNAEGFR
SCHEMBL26807483 0.81 HTR1A (0.41) HTR1AHTR7JAK1SMN1; SMN2LMNA
SCHEMBL29567582 0.81 HTR1A (0.38) HTR1AHTR7JAK1SMN1; SMN2LMNA
SCHEMBL24309633 0.81 HTR1A (0.38) HTR1AHTR7JAK1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HTR1A 4018/4885HTR7 3833/4885JAK1 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback